Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MYGN
MYGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MYGN News
Myriad Genetics Unveils Commercialization Roadmap for Precise MRD Assay
Jan 27 2026
NASDAQ.COM
Myriad Genetics (MYGN) Projects Q4 Revenue of $207M-$209M
Jan 12 2026
NASDAQ.COM
Myriad Genetics CEO Sam Raha to Present at J.P. Morgan Healthcare Conference on Jan 14
Jan 05 2026
Globenewswire
Myriad Genetics Presents Eight Breast Cancer Research Abstracts at SABCS 2025
Dec 09 2025
Newsfilter
Market Update: Health Care Stocks Rise in Premarket Trading on Wednesday
Nov 26 2025
Yahoo Finance
Clairity and Myriad Collaborate to Enhance Breast Cancer Risk Assessment
Nov 25 2025
Newsfilter
What Factors Contributed to Tempus AI Achieving Positive EBITDA in Q3?
Nov 17 2025
NASDAQ.COM
TD Cowen Keeps Hold Rating on Myriad Genetics and Increases Price Target to $9
Nov 04 2025
Benzinga
UBS Keeps Neutral Rating on Myriad Genetics and Increases Price Target to $8
Nov 04 2025
Benzinga
Myriad Genetics Inc. Reports Increased Losses in Q3
Nov 03 2025
NASDAQ.COM
Anticipated Insights from Myriad Genetics (MYGN) Q3 Earnings Report
Nov 02 2025
Yahoo Finance
Breast Cancer Awareness Month: Insights from Patients and Clinicians on Overcoming Fear of Cancer Screenings on YourUpdateTV
Oct 08 2025
Globenewswire
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Sep 23 2025
PRnewswire
Should You Keep MYGN Stock in Your Portfolio at This Time?
Sep 16 2025
NASDAQ.COM
Editorial | Genetic Solutions for Rare Diseases
Sep 12 2025
WSJ
Myriad Genetics Reveals Detailed MRD Clinical Data Published in The Lancet Oncology
Sep 04 2025
Newsfilter
Show More News
